title: Assessment of pathological response to therapy using lipid mass spectrometry imaging.
abstract: In many cancers, the establishment of a patient's future treatment regime often relies on histopathological assessment of tumor tissue specimens in order to determine the extent of the 'pathological response' to a given therapy. However, histopathological assessment of pathological response remains subjective. Here we use MALDI mass spectrometry imaging to generate lipid signatures from colorectal cancer liver metastasis specimens resected from patients preoperatively treated with chemotherapy. Using these signatures we obtained a unique pathological response score that correlates with prognosis. In addition, we identify single lipid moieties that are overexpressed in different histopathological features of the tumor, which have potential as new biomarkers for assessing response to therapy. These data show that computational methods, focusing on the lipidome, can be used to determine prognostic markers for response to chemotherapy and may potentially improve risk assessment and patient care.
authors.affiliation: Department of Chemistry, University of Montreal, Montreal, Quebec, Canada.
authors.forename: Nathan Heath
authors.initials: NH
authors.lastname: Patterson
authors.affiliation: Department of Surgery, McGill University Health Center, Quebec, Canada.|Cancer Research Program, McGill University Health Center-Research Institute, Quebec, Canada.
authors.forename: Balqis
authors.initials: B
authors.lastname: Alabdulkarim
authors.affiliation: Department of Surgery, McGill University Health Center, Quebec, Canada.|Cancer Research Program, McGill University Health Center-Research Institute, Quebec, Canada.
authors.forename: Anthoula
authors.initials: A
authors.lastname: Lazaris
authors.affiliation: Unit of Toxicology, University Centre of Legal Medicine, Geneva-Lausanne, Switzerland.|Faculty of Biology and Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
authors.forename: Aurélien
authors.initials: A
authors.lastname: Thomas
authors.affiliation: Cytochem Inc., 6465 Durocher Avenue, Montreal, Quebec, Canada.
authors.forename: Mieczyslaw M
authors.initials: MM
authors.lastname: Marcinkiewicz
authors.affiliation: Cancer Research Program, McGill University Health Center-Research Institute, Quebec, Canada.|Department of Pathology, McGill University Health Center, Quebec, Canada.
authors.forename: Zu-Hua
authors.initials: ZH
authors.lastname: Gao
authors.affiliation: Translational Cancer Research Unit, GZA Hospitals St.-Augustinus, 2610, Wilrijk, Belgium.
authors.forename: Peter B
authors.initials: PB
authors.lastname: Vermeulen
authors.affiliation: Department of Chemistry, University of Montreal, Montreal, Quebec, Canada.
authors.forename: Pierre
authors.initials: P
authors.lastname: Chaurand
authors.affiliation: Department of Surgery, McGill University Health Center, Quebec, Canada.|Cancer Research Program, McGill University Health Center-Research Institute, Quebec, Canada.
authors.forename: Peter
authors.initials: P
authors.lastname: Metrakos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008055:Lipids / Q000032:analysis*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D008055:Lipids